Research ArticleArticle
Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial
Jeffrey R. Curtis, Theresa McVie, Ted R. Mikuls, Richard J. Reynolds, Iris Navarro-Millán, James O'Dell, Larry W. Moreland, S. Louis Bridges Jr., Veena K. Ranganath and Stacey S. Cofield
The Journal of Rheumatology April 2013, jrheum.120715; DOI: https://doi.org/10.3899/jrheum.120715
Jeffrey R. Curtis
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Theresa McVie
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Ted R. Mikuls
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Richard J. Reynolds
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Iris Navarro-Millán
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
James O'Dell
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Larry W. Moreland
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
S. Louis Bridges Jr.
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Veena K. Ranganath
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Stacey S. Cofield
From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA. Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study. Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche. J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham. Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu. Accepted for publication December 20, 2012.
Article Information
jrheum.120715
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online April 15, 2013.
Article Versions
- You are currently viewing a Latest version of this article (April 15, 2013 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2013 The Journal of Rheumatology
Author Information
- Jeffrey R. Curtis,
- Theresa McVie,
- Ted R. Mikuls,
- Richard J. Reynolds,
- Iris Navarro-Millán,
- James O'Dell,
- Larry W. Moreland,
- S. Louis Bridges Jr.,
- Veena K. Ranganath and
- Stacey S. Cofield
- From the University of Alabama at Birmingham, Birmingham, Alabama; the University of Nebraska Medical Center and Omaha VA Medical Center, Omaha, Nebraska; the University of Pittsburgh, Pittsburgh, Pennsylvania; UCLA (the University of California at Los Angeles), USA.
Support from Amgen. A US National Institutes of Health (NIH) planning grant from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supported the initial phases of the TEAR study.
Dr. Curtis receives support from the NIH (AR 053351) and the US Agency for Healthcare Research and Quality (R01 HS018517) and has received research grants and/or done consulting for Amgen, Abbott, BMS, Crescendo, CORRONA, Genentech, Janssen, Pfizer, and UCB. Dr. Ranganath also receives support from NIH (NIAMS K23 AR057818) and research grants and/or does consulting for BMS and UCB. Dr. Mikuls has received a research grant from Roche.
J.R. Curtis, MD, MS, MPH; T. McVie, MS, University of Alabama at Birmingham; T.R. Mikuls, MD, MSPH, University of Nebraska Medical Center and Omaha VA Medical Center; R. Reynolds, PhD; I. Navarro-Millán, MD, University of Alabama at Birmingham; J. O’Dell, MD, University of Nebraska Medical Center and Omaha VA Medical Center; L.W. Moreland, MD, University of Pittsburgh; S.L. Bridges Jr., MD, PhD, University of Alabama at Birmingham; V.K. Ranganath, MD, University of California at Los Angeles; S.S. Cofield, PhD, University of Alabama at Birmingham.
Address correspondence to Dr. J.R. Curtis, 510 20th Street South, Faculty Office Towers 802 D, Birmingham, AL 35294, USA. E-mail: jcurtis@uab.edu.
Accepted for publication December 20, 2012.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial
Jeffrey R. Curtis, Theresa McVie, Ted R. Mikuls, Richard J. Reynolds, Iris Navarro-Millán, James O'Dell, Larry W. Moreland, S. Louis Bridges, Veena K. Ranganath, Stacey S. Cofield
The Journal of Rheumatology Apr 2013, jrheum.120715; DOI: 10.3899/jrheum.120715
Clinical Response Within 12 Weeks as a Predictor of Future Low Disease Activity in Patients with Early RA: Results from the TEAR Trial
Jeffrey R. Curtis, Theresa McVie, Ted R. Mikuls, Richard J. Reynolds, Iris Navarro-Millán, James O'Dell, Larry W. Moreland, S. Louis Bridges, Veena K. Ranganath, Stacey S. Cofield
The Journal of Rheumatology Apr 2013, jrheum.120715; DOI: 10.3899/jrheum.120715